Skip to main content
. 2019 Nov 13;26(5):623–637.e8. doi: 10.1016/j.chom.2019.09.016

Figure 3.

Figure 3

LN01 Neutralization Breadth, Potency, and Effector Function Killing of HIV-1-Infected Lymphocytes

(A) The neutralizing activity of LN01 IgG1 tested against a cross-clade panel of 118 HIV-1 PVs. The IC50 (top panel) and IC80 (bottom panel) expressed in mg/ml were determined in TZM-bl-cell-based micro-neutralization assay as described in STAR Methods.

(B) Neutralization breadth-potency curves for LN01 and 10E8, with breadth shown as percentage of PVs neutralized at each IC50 (top panel) or IC80 (bottom panel) cutoff (25 μg/mL for LN01 and 10 μg/mL for 10E8).

(C) ADCC killing of HIV-1 infected lymphocytes performed with bnAbs at 15 μg/mL on CEM-NKR-CCR5 cells infected with NLAD8, YU2, CH058, or CH077 HIV-1 strains. ADCC was calculated as the disappearance of Gag+ cells with or without antibodies (n = 6–10), with each dot representing an individual donor of primary NK cell. ADCC responses of each tested antibody were compared to that of the isotype control mGO53 in the Wilcoxon test (∗p < 0.05).

(D) CDC-mediated cell killing performed with bnAbs at 15 μg/mL incubated with a Raji-YU2 Env cell line in the presence of normal human serum from six individual donors or heat-inactivated human serum. The mGO53 antibody was used as a negative control in (C) and (D).